Optivia Receives $1.9M SBIR Grant for Membrane Transporter Research | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Optivia Biotechnology today announced it has been awarded a $1.9 million Phase II Small Business Innovation Research grant to "determine the precise mechanisms that underlie certain drug-to-drug interactions," in an effort to improve medication safety.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.